Fasting Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mg

Mylan

Status and phase

Completed

Phase 1

Conditions

Healthy

Treatments

Drug: Meloxicam Tablets 15 mg

Drug: Mobic® Tablets 15 mg

Study type

Interventional

Funder types

Industry

Identifiers

NCT00649077

MELO-0443

Details and patient eligibility

About

The objective of this study was to investigate the bioequivalence of Mylan's meloxicam 15 mg tablets and Boehringer Ingelheim's Mobic® 15 mg tablets following a single, oral 15 mg (1 x 15 mg) dose administration under fasting conditions.

Enrollment

30 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Age: 18 years and older.
Sex: Male and non-pregnant, non-lactating female.
1. Women of childbearing potential must have negative serum (Beta HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administration. If dosing is scheduled on Sunday or Monday, the HCG pregnancy test should be given within 48 hours prior to dosing of each study period. An additional serum (Beta HCG) pregnancy test will be performed upon completion of the study.
2. Women must practice abstinence or be using an acceptable form of contraception throughout the study. No hormonal contraceptives or hormonal replacement therapies are permitted in this study. Acceptable forms of contraception include the following:
  1. intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study,
  2. barrier methods containing or used in conjunction with a spermicidal agent, or
  3. surgical sterilization
3. Women will not be considered of childbearing potential if one of the following is reported and documented on the medical history:
  1. postmenopausal with an absence of menses for at least one (1) year, or
  2. bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, or
  3. total hysterectomy
4. During the course of the study, from study screen until study exit, all males and women of childbearing potential must use a spermicide-containing barrier method of contraception in addition to their current contraceptive device. This requirement should be documented in the informed consent form.
Weight: At least 60 kg (132 lbs) for man and 48 kg (106 lbs) for women and within 15% of Ideal Body Weight (IBW), as referenced by the Table of ""Desirable Weights of Adults"" Metropolitan Life Insurance Company, 1999 (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).
All subjects should be judged normal and healthy during a pre-study medical evaluation (physical examination, laboratory evaluation, 12-lead ECG, hepatitis B and hepatitis C tests, HIV test, and urine drug screen including amphetamine, barbiturates, benzodiazepine, cannabinoid, cocaine, opiates, phencyclidine, and methadone) performed within 14 days of the initial dose of study medication.

Exclusion criteria

Institutionalized subjects will not be used.
Social Habits:
1. Use of any tobacco products within one year prior to dosing.
2. Ingestion of any alcoholic, caffeine- or xanthine-containing food or beverage within the 48 hours prior to the initial dose of study medication.
3. Ingestion of any vitamins or herbal products within 7 days prior to the initial dose of the study medication.
4. Any recent, significant change in dietary or exercise habits.
Medications:
1. Use of any medication within the 14 days prior to the initial dose of study medication.
2. Use of any medication known to alter hepatic enzyme activity within 28 days prior to the initial dose of study medication.
3. Use of hormonal contraceptives and hormonal replacement therapy within three months prior to the initial dose of study medication.
Diseases:
1. History of any significant chronic disease and/or hepatitis.
2. History of drug and/or alcohol abuse.
3. Acute illness at the time of either the pre-study medical evaluation or dosing.
4. Positive HIV, Hepatitis B, or Hepatitis C test.
Abnormal and clinically significant laboratory test results:
1. Clinically significant deviation from the Guide to Clinically Relevant Abnormalities (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).
2. Abnormal and clinically relevant ECG tracing.
Donation or loss of a significant volume of blood or plasma (> 450 mL) within 28 days prior to the initial dose of study medication.
Subjects who have received an investigational drug within 30 days prior to the initial dose of study medication.
Allergy or hypersensitivity to meloxicam, any of the inactive ingredients, or other related products, such as aspirin or other NSAIDs.
History of difficulties in swallowing, or any gastrointestinal disease which could affect the drug absorption.
Consumption of grapefruit or grapefruit containing products within 7 days of drug administration.